Chronic Nodular Prurigo : A Retrospective Study of 74 Cases
Copyright © 2022 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved..
BACKGROUND AND OBJECTIVE: Chronic nodular prurigo (CNPG) is a recently defined and currently underdiagnosed disease with a variety of causes. It is associated with multiple comorbidities, and its management and treatment have improved with a better understanding of its pathogenesis. The aim of this study was to describe our experience with a series of patients with CNPG.
MATERIAL AND METHODS: Single-center, observational, retrospective study of the sociodemographic and clinical characteristics of patients with CNPG seen at the dermatology department of a tertiary care hospital between 2009 and 2021.
RESULTS: We included 74 patients, mostly women (63.5%), with a mean age of 57 years. Overall, 39.2% of patients had a concomitant skin condition, mainly atopic dermatitis (62%). Other comorbidities included endocrine disorders (54.1%), cardiovascular disease (44.4%), and psychiatric disorders (36.5%). Skin biopsy helped confirm the clinical diagnosis in 70% of cases. The mean immunoglobulin E level was higher than normal (516 IU/mL), regardless of atopic predisposition. On average, patients received 3 treatments, the most common choices being methotrexate, antihistamines, and topical and oral corticosteroids. Methotrexate was among the most effective options.
CONCLUSIONS: CNPG is a complex disease associated with multiple comorbidities. It requires a multidisciplinary approach, with the dermatologist at the center. Classical treatment approaches are probably insufficient.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
---|---|
Enthalten in: |
Actas dermo-sifiliograficas - 113(2022), 9 vom: 03. Okt., Seite 866-873 |
Sprache: |
Englisch |
---|
Weiterer Titel: |
Prurigo crónico nodular: Estudio retrospectivo de 74 casos |
---|
Beteiligte Personen: |
Espiñeira Sicre, J [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 10.10.2022 Date Revised 13.10.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ad.2022.05.018 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM341815195 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM341815195 | ||
003 | DE-627 | ||
005 | 20231226012636.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ad.2022.05.018 |2 doi | |
028 | 5 | 2 | |a pubmed24n1139.xml |
035 | |a (DE-627)NLM341815195 | ||
035 | |a (NLM)35659612 | ||
035 | |a (PII)S0001-7310(22)00467-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Espiñeira Sicre, J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Chronic Nodular Prurigo |b A Retrospective Study of 74 Cases |
246 | 3 | 3 | |a Prurigo crónico nodular: Estudio retrospectivo de 74 casos |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.10.2022 | ||
500 | |a Date Revised 13.10.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
520 | |a BACKGROUND AND OBJECTIVE: Chronic nodular prurigo (CNPG) is a recently defined and currently underdiagnosed disease with a variety of causes. It is associated with multiple comorbidities, and its management and treatment have improved with a better understanding of its pathogenesis. The aim of this study was to describe our experience with a series of patients with CNPG | ||
520 | |a MATERIAL AND METHODS: Single-center, observational, retrospective study of the sociodemographic and clinical characteristics of patients with CNPG seen at the dermatology department of a tertiary care hospital between 2009 and 2021 | ||
520 | |a RESULTS: We included 74 patients, mostly women (63.5%), with a mean age of 57 years. Overall, 39.2% of patients had a concomitant skin condition, mainly atopic dermatitis (62%). Other comorbidities included endocrine disorders (54.1%), cardiovascular disease (44.4%), and psychiatric disorders (36.5%). Skin biopsy helped confirm the clinical diagnosis in 70% of cases. The mean immunoglobulin E level was higher than normal (516 IU/mL), regardless of atopic predisposition. On average, patients received 3 treatments, the most common choices being methotrexate, antihistamines, and topical and oral corticosteroids. Methotrexate was among the most effective options | ||
520 | |a CONCLUSIONS: CNPG is a complex disease associated with multiple comorbidities. It requires a multidisciplinary approach, with the dermatologist at the center. Classical treatment approaches are probably insufficient | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Biopsia cutánea | |
650 | 4 | |a Case series | |
650 | 4 | |a Chronic nodular prurigo | |
650 | 4 | |a Comorbidities | |
650 | 4 | |a Comorbilidades | |
650 | 4 | |a Immunoglobulin E | |
650 | 4 | |a Inmunoglobulina E | |
650 | 4 | |a Multidisciplinar | |
650 | 4 | |a Multidisciplinary | |
650 | 4 | |a Prurigo crónico nodular | |
650 | 4 | |a Prurito | |
650 | 4 | |a Pruritus | |
650 | 4 | |a Serie de casos | |
650 | 4 | |a Skin biopsy | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Histamine Antagonists |2 NLM | |
650 | 7 | |a Immunoglobulin E |2 NLM | |
650 | 7 | |a 37341-29-0 |2 NLM | |
650 | 7 | |a Methotrexate |2 NLM | |
650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
700 | 1 | |a Docampo Simón, A |e verfasserin |4 aut | |
700 | 1 | |a Silvestre Salvador, J F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Actas dermo-sifiliograficas |d 1945 |g 113(2022), 9 vom: 03. Okt., Seite 866-873 |w (DE-627)NLM000271438 |x 1578-2190 |7 nnns |
773 | 1 | 8 | |g volume:113 |g year:2022 |g number:9 |g day:03 |g month:10 |g pages:866-873 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ad.2022.05.018 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 113 |j 2022 |e 9 |b 03 |c 10 |h 866-873 |